Keros Therapeutics (KROS) announced that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes. The dosing of the first patient triggers a $10 million milestone payment to Keros under the global license agreement with Takeda (TAK). Under the terms of the global license agreement with Takeda to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, which became effective on January 16, 2025, Keros received a $200 million upfront cash payment in February 2025, and is eligible to receive development, commercial and sales milestones with the potential to exceed $1.1 billion. Keros will also be eligible to receive tiered royalties on net sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics Announces CMO Resignation
- McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls
- Keros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside
- Keros Therapeutics downgraded to Neutral from Buy at BofA
- ADAR1 says Keros needs ‘fresh perspectives in the boardroom’